KHK-2455 is under clinical development by Kyowa Kirin and currently in Phase I for Adrenal Gland Cancer. According to GlobalData, Phase I drugs for Adrenal Gland Cancer have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KHK-2455’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KHK-2455 is under development for the treatment of head and neck cancer, ovarian cancer, osteosarcoma, pancreatic cancer, gastric cancer, gallbladder cancer and adrenal cancers. The drug candidate is administered through oral route and formulated as a solid encapsulated dosage form. KHK-2455 acts by targeting IDO-1. It is a new molecular entity (NME). It was also under development for urothelial carcinoma, advanced or metastatic solid tumors including metastatic urothelial tract cancer, bladder cancer, urethral cancer, ureter cancer, renal pelvis cancer.
Kyowa Kirin overview
Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
For a complete picture of KHK-2455’s drug-specific PTSR and LoA scores, buy the report here.